Senores Pharmaceuticals Peer Comparison

Senores Pharmaceuticals Ltd. shows significant growth potential but is currently overvalued compared to peers. While its long-term revenue growth is commendable, the extremely high PE ratio indicates that it may be priced for perfection. In contrast, companies like Cipla and Dr. Reddy’s Laboratories represent strong overall performers with attractive valuations and solid profitability metrics.

• • Senores Pharmaceuticals Ltd. has the highest 3-year revenue growth at 41.12%.
• • Cipla Ltd. and Dr. Reddy's Laboratories Ltd. demonstrate strong profitability with ROE values above 16%.
• • Senores Pharmaceuticals Ltd. is significantly overvalued with a PE ratio of 875.69, while peers like Cipla and Dr. Reddy's offer more attractive valuations.
• • Mankind Pharma Ltd. shows robust growth with a revenue YoY increase of 18.12%.
• • Divi's Laboratories Ltd. is financially weak with a very high debt-to-equity ratio and declining revenue.

• • Cipla Ltd.: Strong profitability metrics and low valuation ratios.
• • Dr. Reddy's Laboratories Ltd.: Consistent growth and attractive valuation with a PE of 15.50.
• • Mankind Pharma Ltd.: High growth potential with a strong 3-year revenue increase.